Insights into E3805: The CHAARTED trial

Future Oncology

Volumn 11, Issue 6, 2015, Pages 897-899

  Sweeney, Christopher J ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

androgen deprivation therapy; docetaxel; hormone sensitive metastatic prostate cancer

Indexed keywords

DOCETAXEL; ANTINEOPLASTIC AGENT;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RESEARCH; HEALTH CARE PERSONNEL; HOSPITAL; HUMAN; MEDICAL ONCOLOGIST; ONCOLOGY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RADIATION ONCOLOGIST; UROGENITAL TRACT CANCER; UROLOGIST; INTERVIEW; MALE; PROSTATIC NEOPLASMS; RESEARCH; TRENDS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MALE; MEDICAL ONCOLOGY; PROSTATIC NEOPLASMS; RESEARCH;

EID: 84925012755     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.310     Document Type: Article

References (0)